{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:17Z","timestamp":1787836937676,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Nirsevimab prevents respiratory syncytial virus (RSV)-associated hospitalizations in infants. However, its impact on the broader epidemiology of acute respiratory infections (ARI) in hospitalized children remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective study of ARI hospitalizations among children aged \u22645 years at a tertiary pediatric hospital in Parma, Emilia Romagna region, Italy, across 3 respiratory seasons (from September 1, 2022 to April 30, 2025), spanning the period before and after nirsevimab introduction (October 2024). All children hospitalized with ARI during the seasonal period (September\u2013April) who tested positive for at least 1 respiratory virus by multiplex polymerase chain reaction were included. We analyzed temporal trends in ARI hospitalization rates, viral distribution and RSV-specific infection patterns. Hospitalization rates were contextualized using the resident population aged \u22645 years in Emilia Romagna.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 241 ARI hospitalizations were included, with 347 viral detections, of which 44.7% were monoinfections and 55.3% were coinfections. The incidence of ARI hospitalizations decreased in the 2024\u20132025 season compared with the previous 2 seasons (from 14.3 to 2.2 per 100 person-months). The overall distribution of respiratory viruses remained stable over time\n                      <jats:italic toggle=\"yes\">(P<\/jats:italic>\n                      -trend = 0.4736), with RSV and rhinovirus accounting for approximately 35% and 30% of detections, respectively. The proportion of RSV monoinfections remained unchanged, whereas RSV coinfections declined significantly (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -trend = 0.0161).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Following nirsevimab introduction, pediatric ARI hospitalizations declined without evidence of viral replacement. The selective reduction in RSV coinfections suggests that RSV prevention may reduce infection complexity in addition to RSV-associated disease. Continued surveillance is needed to assess the long-term epidemiologic impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005374","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:00:18Z","timestamp":1787198418000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact on Pediatric Respiratory Virus Epidemiology Following Nirsevimab Introduction"],"prefix":"10.1097","author":[{"given":"Costanza","family":"Di Chiara","sequence":"first","affiliation":[{"name":"Department for Women\u2019s and Children\u2019s Health, University of Padova, Padova, Italy"},{"name":"Child Health Evaluative Sciences, Center for Global Child Health, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Rigamonti","sequence":"additional","affiliation":[{"name":"Societ\u00e0 Servizi Telematici\u2014Pedianet, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Rita","family":"Campana","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Parma University Hospital, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0014-7574","authenticated-orcid":false,"given":"Delia","family":"Monopoli","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Parma University Hospital, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajrie","family":"Seferi","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Parma University Hospital, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9120-0424","authenticated-orcid":false,"given":"Alberto","family":"Villani","sequence":"additional","affiliation":[{"name":"General Pediatric and Infectious Disease Unit, Pediatric Emergency Medicine, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy"},{"name":"Systems Medicine Departments, Tor Vergata University of Rome, Rome, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Vittucci","sequence":"additional","affiliation":[{"name":"General Pediatric and Infectious Disease Unit, Pediatric Emergency Medicine, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Antilici","sequence":"additional","affiliation":[{"name":"General Pediatric and Infectious Disease Unit, Pediatric Emergency Medicine, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0600-7745","authenticated-orcid":false,"given":"Giulia","family":"Brigadoi","sequence":"additional","affiliation":[{"name":"Department for Women\u2019s and Children\u2019s Health, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Don\u00e0","sequence":"additional","affiliation":[{"name":"Department for Women\u2019s and Children\u2019s Health, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-780X","authenticated-orcid":false,"given":"Anna","family":"Cantarutti","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milano, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Parma University Hospital, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"R1-20260827","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"R2-20260827","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","article-title":"The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study.","volume":"11","author":"Wildenbeest","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R3-20260827","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in Infants.","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med"},{"key":"R4-20260827","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"R5-20260827","doi-asserted-by":"crossref","first-page":"580","DOI":"10.15585\/mmwr.mm7437a1","article-title":"Nirsevimab effectiveness against intensive care unit admission for respiratory syncytial virus in infants\u201424 states, December 2024-April 2025.","volume":"74","author":"Zambrano","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R6-20260827","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2352-4642(25)00093-8","article-title":"Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis.","volume":"9","author":"Sumsuzzman","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"R7-20260827","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400275","article-title":"Nirsevimab effectiveness at preventing RSV-related hospitalization in infants.","volume":"4","author":"Jabagi","year":"2025","journal-title":"NEJM Evid"},{"key":"R8-20260827","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/QCO.0000000000001008","article-title":"Impact of respiratory viral infections on nasopharyngeal pneumococcal colonization dynamics in children.","volume":"37","author":"Howard","year":"2024","journal-title":"Curr Opin Infect Dis"},{"key":"R9-20260827","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.98.2534.87.b","article-title":"Interference of inactive virus with the propagation of virus of influenza.","volume":"98","author":"Henle","year":"1943","journal-title":"Science"},{"key":"R10-20260827","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference I. The interferon.","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"R11-20260827","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3201\/eid2802.211727","article-title":"Viral interference between respiratory viruses.","volume":"28","author":"Piret","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"R12-20260827","doi-asserted-by":"crossref","first-page":"e70105","DOI":"10.1111\/irv.70105","article-title":"Impact of nirsevimab on RSV and Non-RSV severe respiratory infections in hospitalized infants.","volume":"19","author":"Garc\u00eda-Garc\u00eda","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"key":"R14-20260827","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3390\/vaccines13090896","article-title":"Acceptance of nirsevimab for the prevention of respiratory syncytial virus infection in neonates: a cross-sectional survey in Emilia-Romagna, Italy.","volume":"13","author":"Esposito","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"R15-20260827","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamapediatrics.2026.0657","article-title":"Nirsevimab immunization to prevent pediatric RSV hospitalizations.","volume":"180","author":"Attaianese","year":"2026","journal-title":"JAMA Pediatr"},{"key":"R16-20260827","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamapediatrics.2025.5280","article-title":"Nirsevimab against hospitalizations and emergency department visits for lower respiratory tract infection in infants: a meta-analysis.","volume":"180","author":"Sumsuzzman","year":"2026","journal-title":"JAMA Pediatr"},{"key":"R17-20260827","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1473-3099(25)00742-X","article-title":"Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study.","volume":"26","author":"Razzini","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"R18-20260827","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.259871","article-title":"Respiratory syncytial virus disrupts the airway epithelial barrier by decreasing cortactin and destabilizing F-actin.","volume":"135","author":"Gao","year":"2022","journal-title":"J Cell Sci"},{"key":"R19-20260827","first-page":"800","article-title":"New insights on the viral and host factors contributing to the airway pathogenesis caused by the respiratory syncytial virus.","volume":"42","author":"Lay","year":"2016","journal-title":"Crit Rev Microbiol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:00:35Z","timestamp":1787835635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":18,"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005374","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}